1.5 billion people worldwide suffer from chronic (recurrent and long-lasting) pain, in the US alone this exerts more than a $600 billion drain on the US economy annually due to lost productivity. The prevalence of pain conditions must be addressed in a comprehensive, all-encompassing manner. To seek explanation for the variability of opioid response is one of many important facets in easing the burden of chronic pain upon our society, as is understanding the heritability of pain.
Human pain phenotypes can be identified via genetic testing to ascertain genetic basis of pain variability. Pharmacogenetics can identify patients at risk of drug intolerance, drug-drug interactions, explain adverse events or therapeutic failure, as well as develop genetic profiles to predict the aforementioned outcomes. Researchers may now use genetic testing to aid the discovery of new, safer and more effective therapeutics.
This exclusive webinar will explore the following considerations:
- The epidemiology of pain and its impact upon quality-of-life
- Patho-physiology of pain
- Heritability and genetics of pain
- Pharmacogenetics of pain receptors, signaling, and metabolism of pain medications
- Applying gene testing in analgesic clinical drug development
Dr. Lynn Webster, MD Vice President, Scientific Affairs, PRA Health Sciences Past President, American Academy of Pain Medicine
Dr. Webster serves as Vice President of Scientific Affairs at PRA Health Sciences. He was co-founder and Chief Medical Director of Lifetree Clinical Research* (formerly CRI Lifetree). Dr. Webster’s research interests are diverse, and he is keenly interested in working with industry to develop safer and more effective therapies for chronic pain and addiction. He is a leading researcher in exploring the relationship of medications and sleep, with particular interest in analgesic-induced sleep-disordered breathing. Dr. Webster is board certified in anesthesiology and pain medicine and is also certified in addiction medicine. He earned his doctorate of medicine from the University of Nebraska Medical Center and completed his residency in the University of Utah Medical Center’s department of anesthesiology.Message Presenter
Who Should Attend?
- “C-Level” Executives – CSO/CMO
- Drug Developers in the CNS/Pain/Addiction Therapy fields
- Heads of Global Clinical Development
- Patient Recruitment and Retention professionals
- Senior Physicians/ Prescribers of opioid medications
- Clinical Trial Planning and Optimization
At PRA Health Sciences, providing innovative solutions for our clients is what we do. But innovation just for the sake of innovation isn’t why we do it. Side-by-side with our clients, we strive to move drug discovery forward, to help them develop life-saving and life- improving drugs. We help change people’s lives for the better every single day. It’s who we are. Innovating to help people is at the heart of our process, but it’s even more than that. It’s also our privilege.